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a  b  s  t  r  a  c  t
MicroRNA  expression  appears  to  capture  the process  of  neoplastic  development  in vitro in the  VERO  line
of African  green  monkey  kidney  (AGMK)  cells  (Teferedegne  et  al. PLoS  One  2010;5(12):e14416).  In  that
study,  speciﬁc  miRNA  signatures  were  correlated  with  the transition,  during  serial  tissue-culture  passage,
of low-density  passaged  10–87  VERO  cells  from  a non-tumorigenic  phenotype  at passage  (p)  148 to  a
tumorigenic  phenotype  at p256.  In  the present  study,  six  miRNAs  (miR-376a,  miR-654-3p,  miR-543,  miR-
299-3p,  miR-134  and  miR-369-3p)  were  chosen  from  the  identiﬁed  signature  miRNAs  for  evaluation  of
their  use  as  potential  biomarkers  to track  the  progression  of  neoplastic  development  in VERO  cells.  Cells
from  the  10–87  VERO  cell line  at passage  levels  from  p148  to p256  were  inoculated  into  newborn  and
adult  athymic  nude  mice.  No  tumors  were  observed  in animals  inoculated  with  cells from  p148 to  p186.
In  contrast,  tumor  incidences  of 20%  developed  only  in  newborn  mice  that  received  10–87  VERO  cells  at
p194,  p234  and  p256.  By  qPCR  proﬁling  of the signature  miRNAs  of  10–87  VERO  cells  from  these  cell banks,
we  identiﬁed  p194  as  the  level  at which  signature  miRNAs  elevated  concurrently  with  the  acquisition
of  tumorigenic  phenotype  with  similar  levels  expressed  beyond  this  passage.  In  wound-healing  assays
at 10-passage  intervals  between  p150  to  p250,  the cells  displayed  a progressive  increase  in  migration
from  p165  to p186;  beginning  at p194  and  higher  passages  thereafter,  the  cells  exhibited  the  highest
rates  of migration.  By qPCR  analysis,  the same  signature  miRNAs  were  overexpressed  with  concomitant
acquisition  of the tumorigenic  phenotype  in another  lineage  of 10–87  VERO  cells  passaged  independently
at  high  density.  Correlation  between  the  passages  at which  the cells  expressed  a tumorigenic  phenotype
and  the passages  representing  peaks  in  expression  levels  of signature  miRNAs  indicates  that  these  miRNAs
are potential  biomarkers  for the expression  of  the  VERO  cell  tumorigenic  phenotype.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license. Introduction
The VERO cell line represents a well-characterized, immortal-
zed line of African green monkey kidney (AGMK) cells that is
usceptible to a broad range of viruses [1–4]. These cells are used
s the cell substrate reagents for the manufacture of several viral
accines including vaccines against poliomyelitis, rabies, rotavirus,
mallpox, and inﬂuenza [2–8]. VERO cells at passages (p) 140 to 165
re non-tumorigenic in immunocompromised mice [9–11]; how-
ver, the VERO cell phenotype can evolve by prolonged passage
n culture to become tumorigenic in these mice [10,12]. Candidate
∗ Corresponding authors. Tel.: +1 301 827 0650; fax: +1 301 496 1810.
E-mail addresses: belete.teferedegne@fda.hhs.gov (B. Teferedegne),
ndrew.lewis@fda.hhs.gov (A.M. Lewis Jr.).
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.065
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/3.0/).
cell substrate reagents proposed for the production of biologics for
human use need to be carefully characterized. For the characteri-
zation of immortalized cells, the cell line must be described with
respect to its tumorigenicity in animal models (21 Code of Federal
Regulations 610.18). Besides the obvious high cost and time associ-
ated with animal assays, there is a goal to reduce, reﬁne, or replace
animal testing. Thus, developing predictive molecular markers that
can be used as assays to replace in vivo tests for the characterization
of cell substrate tumorigenicity could help meet these goals.
A recent development in cell biology has been the identiﬁcation
of the role of microRNAs (miRNAs) in the modulation of various cel-
lular processes. miRNAs are short, non-coding RNAs that regulate
the expression of many target genes. miRNAs have been shown to
play critical regulatory roles in a wide range of biological and patho-
logical processes including cancer. The involvement of miRNAs in
cancer initially emerged from both studies showing their proximity
D license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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o chromosomal break points [13] and their deregulated expression
evels in many neoplastic tissues compared with normal tissues
14–23]. Moreover, the identiﬁcation of classical oncogenes and
umor suppressor genes as direct targets of miRNAs has led to the
onclusion that miRNAs play crucial roles in cancer initiation, pro-
ression, and metastasis [17,24–27]. Hence, given the critical role
iRNAs play in the process of tumorigenesis and in their disease-
peciﬁc expression, they hold potential as novel biomarkers and
herapeutic targets.
In an earlier study, we found that speciﬁc miRNA signatures cor-
elated with the transition of the 10–87 VERO line of AGMK cells
rom a non-tumorigenic phenotype at low passage p140 cells to
 tumorigenic phenotype at high passage p250 cells during serial
issue-culture passage [28]. In the current study, we have expanded
his observation to determine whether these miRNA signatures
ight be used as biomarkers of the 10–87 VERO cell tumorigenic
henotype. The pattern of these potential miRNA signatures was
ssessed in cell banks established at every 10 passages from p140
o p250 at low density (LD). We  found a correlation between the
assages at which the VERO cells expressed a tumorigenic pheno-
ype and the passages representing the peak in expression levels of
ignature miRNAs. This correlation was conﬁrmed using another
ineage of 10–87 VERO cells derived by passage at high density
HD) to evaluate the impact of plating density on the evolution of
he VERO neoplastic phenotype. These results illustrate that these
iRNAs can be potential biomarkers for the expression of the VERO
ell tumorigenic phenotype.
. Materials and methods
A more detailed presentation of Section 2 is found in Supple-
ental Materials and methods.
.1. Cell lines and cell culture
Cells from the World Health Organization (WHO) VERO cell bank
0–87 (ATCC 10–87 VERO cells) were serially passaged in Dul-
ecco’s Modiﬁed Eagle’s Medium (DMEM) (Mediatech, Manassas,
A) supplemented with 10% fetal bovine serum (Hyclone, Logan,
T) and 2 mM l-glutamine (Mediatech, Manassas, VA) (DMEM-10)
rom p134 to p250 by sub-culturing VERO cells either before [10]
r after they reached conﬂuence. For the studies in this report, the
ub-conﬂuent passaged 10–87 VERO cells were designated as low-
ensity passage 10–87 VERO cells (LD 10–87 VERO cells), while
0–87 VERO cells passaged at conﬂuence were designated as high-
ensity passaged 10–87 VERO cells (HD 10–87 VERO cells). The
opulation doubling times (PDT) for LD 10–87 VERO cells and HD
0–87 VERO cells at p 250 were 26 h for the LD 10–87 VERO cells
nd 20 h for the HD 10–87 VERO cells. The LD and HD passaged
ells used in this study and some of the tumors they formed were
onﬁrmed to be of simian origin by karyotyping and by PCR using
rimers that recognize simian SINE sequences [28]. These cells have
lso been found to be free of 26 rodent viruses and mycoplasma
amilies (Radil, Columbia, MO).
.2. Tumorigenicity assays
Adult (10 mice/dose) and newborn (NB) (3 litters/dose) athymic
ude mice were inoculated subcutaneously (107 cells/mouse in
.1 mL  of PBS per cell line) above the scapulae. Tumors were docu-
ented to grow progressively by measurements in two dimensions
ntil they were 15–20 mm in size, at which point the animals
ere euthanized. The tumor incidence in adult and newborn nude
ice was recorded at weekly intervals over 12 month observation
eriods and plotted as survival curves. 32 (2014) 4799–4805
2.3. Wound-healing assays
Wound-healing assays were performed as previously described
[29] with some modiﬁcations. Cells were plated 1 × 106 cells/plate
in 60-mm culture dishes (Corning, Corning, NY) and allowed to
form monolayers. When the cultures reached 90% conﬂuence, they
were serum starved for 8 h and the monolayers were wounded with
a P200 micropipette tip, washed with PBS and cultured in DMEM-
10. Images of cell migration into the wounded areas were captured
at 0, 3, 6, 9, 12 and 15 h.
2.4. Quantitative RT-PCR
Total RNA from primary (p) African green monkey kidney
(AGMK) cells and from cells from LD 10–87 VERO and HD 10–87
VERO cell banks established at every 10 passages from p140 to p250
was extracted and puriﬁed using the miRNeasy mini kit according
to the manufacturer (Qiagen Inc., Valencia, CA). The expression of
signature miRNAs of these samples was  measured using the Taq-
Man  miRNA quantitative PCR assay [30]. Expression values were
normalized to a small nucleolar RNA, RNU6 (Applied Biosystems).
Ct values were calculated using the Ct values of the miRNA and
the RNU6 for each corresponding sample. Ct values are calcu-
lated using the Ct values of the pAGMK cells and the experimental
cell lines for each miRNA. The fold change over pAGMK was calcu-
lated.
3. Results
To pursue our investigation of the possible correlation between
signature miRNA expression and the tumor-forming ability of VERO
cells, we  extended our study of the relationship between tumori-
genicity in vivo, wound-healing assays in vitro, which are frequently
correlated with tumor-forming ability, and the patterns of expres-
sion of speciﬁc signature miRNAs. Correlation was sought across
a range of 10–87 VERO cell passages at 10-passage intervals from
p150 to p250 between the expression of 6 signature miRNAs and
the evolution to a tumorigenic phenotype as indicated by tumor
formation in athymic nude mice and in vitro wound-healing assays.
Data obtained using the original LD 10–87 VERO cell line, which
was established by passaging before the cell monolayer reached
conﬂuence, were conﬁrmed and extended using another lineage
of 10–87 VERO cells derived by passage at high density to evalu-
ate the impact of plating density on the evolution of the VERO cell
neoplastic phenotype.
3.1. VERO cell tumorigenicity
To evaluate the progression of the neoplastic phenotype
expressed at intervening passages between p150 and p256 and to
identify the passages at which the cells expressed a tumorigenic
phenotype, LD 10–87 VERO cells and HD 10–87 VERO cells at dif-
ferent passage levels were inoculated into adult and newborn nude
mice (NB). No tumors (0/70) were observed in adult nude mice
inoculated with p157–p254 LD 10–87 VERO (data not shown) or in
newborn nude mice (0/39) inoculated with p157–p185 LD 10–87
VERO cells after one year (Fig. 1). A maximum of 20% tumor inci-
dences at the site of inoculation were recorded in NB mice that
received LD 10–87 VERO cells at p194, p234, or p254 (Fig. 1). Inci-
dence of tumor formation did not increase with the increasing
passage level of the LD VERO cells.
In the NB nude mice inoculated with the LD 10–87 VERO cells
at p194, the ﬁrst tumor appeared at 8 weeks and the second tumor
appeared at 10 weeks; in NB mice inoculated with the p234 VERO
cells, tumors appeared at 16 and 19 weeks. In NB mice inoculated
with LD 10–87 VERO cells at p254, the ﬁrst tumor appeared at 7
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Fig. 1. Low-density passage (LD) VERO cells at their different passage levels were
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inoculated into newborn and adult athymic nude mice. Twenty percent tumor inci-
ences were recorded in newborn mice that received p194, p234 and P254 VERO
ells. Numbers in parenthesis are tumor incidence.
eeks and the second tumor appeared at 48 weeks. Time of tumor
ppearance (latency) did not correlate with passage level in nude-
ouse assays involving LD 10–87 VERO cells. The tumor incidencen animals inoculated with HD 10–87 VERO cells differed compared
ith the results with the LD 10–87 VERO cells (Fig. 2A and B). The
arliest passage that HD 10–87 VERO cells formed tumors in NB
ig. 2. High-density passage (HD) VERO cells at their different passage levels
ere inoculated into newborn (A) and adult (B) athymic nude mice. Tumors were
bserved in newborn mice that received HD VERO cells at passages ≥p185. Numbers
n  parenthesis are tumor incidence.
Fig. 3. Rate of migration progressively increased with increasing passages of (A)
low-density passage (LD) and (B) high-density passaged (HD) VERO cells. Cells were
seeded in 60-mm dishes (2 × 106 cells/dish) and serum-starved for 8 h. After scratch-
ing  the monolayer with a 200-L-pipette tip, cells were washed with PBS, cultured
in  DMEM-10, and photographed under a 4× objective every 3 h for 15 h. Only the 0
and  12 h images are shown. Arrows indicate borders of migrating cells.
(5/10) and adult (1/10) nude mice was  at p184 compared with p194
for LD 10–87 VERO cells. By 36 weeks, HD 10–87 VERO cells at
p256 had formed tumors in 100% (8/8) of the NB nude mice; by 50
weeks, a tumor incidence of 20% (2/10) was  observed in the nude
mice inoculated as adults (Fig. 2B). The majority (20/21) of tumors
in NB and adult nude mice inoculated with HD 10–87 VERO cells
appeared between 13 and 25 weeks indicating that the incidence
of tumor formation was enhanced by HD serial passage. In these
assays, tumor formation occurred only at the site of inoculation;
no spontaneous tumors were detected in these animals during the
course of the assay.
3.2. Rate of migration of VERO cells
In our initial study, we found that increased rates of 10–87 VERO
cell migration in wound-healing assays correlated with their capac-
ity to form tumors in vivo [28]. For our current study, we used
wound-healing assays to examine the rates of migration of cell
lines established from LD 10–87 VERO cells and HD 10–87 VERO
cells at 10 passage intervals. After the monolayer was scratched
with a pipette tip, the migration of cells into the wounded area were
photographed every 3 h for 15 h. Representative photomicrographs
are shown of wounded cell-culture monolayers at 0 and 12 h. Red
arrows represent absence of cell migration into the wounds. The
non-tumorigenic LD 10–87 VERO cells at p151 and tumorigenic LD
10–87 VERO cells at p256 were used as references lines for slowly
and rapidly migrating cells, respectively. The tumorigenic LD 10–87
VERO cells at p256 started ﬁlling the wound around 9 h and com-
pletely closed the wound by 12 h, whereas little or no motility was
observed with LD 10–87 VERO at p151 (Fig. 3A). When we tested LD
10–87 VERO cells at 10-passage intervals between p151 to p256,
the cells displayed a progressive increase in migration rates from
4802 B. Teferedegne et al. / Vaccine 32 (2014) 4799–4805
Table 1
Expression levels of miRNAs in low density passaged VERO cells and A4497 VERO cells using Taqman quantitative RT-PCR1.
miRNA LD VERO (p154) LD VERO (p174) LD VERO (p194) LD VERO (p254) HP A4497 VERO
miR-376a 2.0 10.2 42.7 27.7 42.4
miR-654-3p 1.0 2.0 22.5 20.0 38.6
miR-543 2.0 5.2 34.6 25.0 26.2
miR-299-5p 2.9 4.3 31.2 22.7 43.6
miR-134 1.0 2.2 10.1 22.8 30.1
miR-369-3p 1.0 2.7 8.8 23.3 24.6
1Results from the triplicate samples were averaged following normalization to the levels of small RNA U6B. The data were presented as fold change over pAGMK miRNA
levels. The ANOVA analysis of the miRNAs was signiﬁcant with at least p < 0.01.
Table 2
Expression level of miRNA in high density passaged VERO cells using Taqman quantitative RT-PCR1.
miRNA HD VERO (p153) HD VERO (p163) HD VERO (p173) HD VERO (p183) HD VERO (p196) HD VERO (p250)
miR-376a 1.1 2.5 2.0 12.0 25.9 56.4
miR-654-3p 1.8 2.4 2.5 8.2 17.2 34.9
miR-543 1.1 2.6 3.0 9.7 25.3 48.6
miR-299-5p 1.7 2.1 2.6 5.4 5.5 14.3
miR-134 1.0 1.2 1.3 2.1 1.6 6.1
miR-369-3p 3.5 3.9 3.6 4.9 5.0 19.0
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of neoplastic development in VERO cells. To verify the accuracy
and speciﬁcity of these results, we assessed the six miRNAs in HD
VERO cells that were passaged independently at higher, conﬂuentResults from the triplicate samples were averaged following normalization to the
evels. The ANOVA analysis of the miRNAs was signiﬁcant with a p < 0.01.
165 to p186, and the wound was completely closed by LD 10–87
ERO cells at p194.
In a similar fashion, HD 10–87 VERO cells displayed a progres-
ive increase in migration rate from p165 to p195 (Fig. 3B). The rate
t which the HD 10–87 VERO cells migrate was somewhat faster
han the LD VERO cells, since as the wound completely closed at
185 as opposed to p194 for LD VERO cells.
Both LD and HD VERO cells appeared to migrate predominantly
s tightly packed sheets in a wound-healing assay. Since doubling
imes for both LD (26 h) and HD VERO (20 h) cells are greater than
he assay time (12 h), it is unlikely that the differences in migration
bserved were affected by the rate of proliferation of the respective
ells.
.3. Signature miRNAs as potential biomarkers of the VERO cell
umorigenic phenotype
In our earlier study, 10 speciﬁc signature miRNAs were iden-
iﬁed that correlated with the transition of LD 10–87 VERO cells
rom a non-tumorigenic phenotype at p148 to a tumorigenic phe-
otype at p256 [28]. The 10 signature miRNAs were differentially
verexpressed in tumorigenic, high-passage LD 10–87 VERO cells
ompared with non-tumorigenic, low-passage LD 10–87 VERO
ells. Based on their level of expression, six miRNAs (miR-376a,
iR-654-3p, miR-543, miR-299-3p, miR-134 and miR-369-3p)
ere chosen for evaluation of their use as potential biomarkers
o track the progression of neoplastic development in VERO cells.
sing RNA samples prepared from LD 10–87 VERO cell banks
stablished at every 10 passages from p150 to p254, the level of
xpression of the selected miRNAs was examined by quantitative
T-PCR. The expression levels of these miRNAs in non-tumorigenic
D 10–87 VERO cells (p154) were slightly above background levels
f pAGMK cells. In contrast, the expression levels of these miRNAs
ncreased progressively by at least 2-10 fold at p174 and by greater
han 8-42 fold (p < 0.01) at p194 compared with pAGMK cells
Table 1). Higher than 20-fold levels of expression (p < 0.01) was
ustained in LD 10–87 VERO cells at p250 and in A4497 (p > 200)
ERO cells, which are tumorigenic in both newborn and adult nude
ice [10]. Three of the six miRNAs (miR-376a, miR-543 and miR-
99-3p) were overexpressed more than 4-10 fold compared with
AGMK control cells and the LD 10–87 VERO cell passages before
he expression of the tumorigenic phenotype was detected at p194s of small RNA U6B. The data were presented as fold change over pAGMK miRNA
(Table 1 and Fig. 1A). These results suggest that these miRNA-based
biomarkers may  be capable of predicting the pre-tumor stagesFig. 4. Individual miRNAs can be used to detect the expression of tumorigenic phe-
notype in VERO cells. The relative expression levels of the miRNAs were measured
by  the Taqman probe-based qRT-PCR. The curves for (A) LD and (B) HD VERO cells
were plotted to demonstrate the diagnostic value of each miRNA for detecting the
expression of tumorigenic phenotype in VERO cells.
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ensities. The trend in the alteration of miRNA expression was
enerally similar between the LD 10–87 VERO cell lines and the HD
0–87 VERO cell lines. When compared with the pAGMK controls,
ve of these six miRNAs were over-expressed by greater than
-fold in the tumorigenic HD 10–87 VERO cells at p183, and all six
ere over-expressed by 6- to >50-fold at p250 (Table 2).
To further evaluate the ability of individual miRNA to reﬂect the
xpression of the tumorigenic phenotype in VERO cells, we  exam-
ned three miRNA data sets (miR-376a, miR-654-3P, and miR-543)
rom experiments shown in Tables 1 and 2. The expression pat-
ern of each of these miRNA followed the progression of neoplastic
evelopment and peaked at p194 (Fig. 4A) where the ability of
D 10–87 VERO cells to form tumors was detected (Fig. 1). In HD
0–87 VERO cells, the same association between elevated expres-
ion levels of the same miRNAs and tumorigenicity was observed
t p183; however, the expression levels in cells at p250 increased
y an additional 4-fold compared with cells at p183 (Fig. 4B).
ogether, regardless of how the tumor-forming cells were estab-
ished, whether by passaging at low density or high density, the
ndividual miRNA expression pattern correlated with the detec-
ion of the tumorigenic phenotype. Therefore, these six miRNAs
ppeared to be biomarkers for this property of VERO cells.
. Discussion
Managing the threats posed by emerging and re-emerging
nfectious diseases, such as pandemic inﬂuenza, call for the rapid
roduction of large, possibly unprecedented, amounts of vaccines
o immunize populations worldwide [31–33]. Current produc-
ion methods may  be insufﬁcient to meet these demands in the
hort period required to manage pandemics successfully [33].
ell-culture technology based on immortalized cell substrates pro-
ides a possible method for increasing the efﬁciency of vaccine
anufacture and improving vaccine efﬁcacy [1,3,6,8,31,32,34–37].
egulatory agencies have recommended that the tumorigenic
otential of immortalized cell substrates proposed for human vac-
ine production be evaluated (21 Code of Federal Regulations
10.18). Here, we have used VERO cells as the ﬁrst model to
emonstrate the proof-of-concept for miRNA proﬁling as a poten-
ial surrogate for tumorigenicity testing. As neoplastic progression
eading to the development of the tumorigenic phenotype is driven
y molecular alterations, the analysis of these molecular features
ould contribute to the prediction of the tumorigenic potential of
ell substrates that evolve by spontaneous neoplastic development
uring cell culture.
MicroRNAs are short RNA molecules that have been shown to
e important regulators of biological functions [38]. Aberrations in
iRNA expression can affect important cellular processes like the
ell cycle, cell proliferation, or cell death by apoptosis [39]. These
rocesses are known to be involved in neoplastic development and
ence provide a direct link to tumor initiation and progression. The
se of tissue miRNA expression proﬁles as diagnostic or progno-
tic biomarkers in cancer has been demonstrated by several studies
24,40].
We have shown that speciﬁc miRNA signatures were identiﬁed
hat correlated with the transition of VERO cells from a non-
umorigenic phenotype (low-passage cells, p148) to a tumorigenic
henotype (high-passage cells, p256) during serial tissue-culture
assage [28]. We  also demonstrated that the signature miRNAs
dentiﬁed in VERO cells grown in FBS were the same as in the
ERO cells adapted to grow in serum-free medium (SF-VERO). In
he present study, we used quantitative RT-PCR to evaluate our ini-
ial observation that miRNA expression changes with the progress
f neoplastic development of VERO cells during intervening pas-
ages. Compared with pAGMK cells, the expression levels of these 32 (2014) 4799–4805 4803
signature miRNAs progressively increased in cells from LD 10–87
VERO cell banks established at every 10 passages from p151 to
p256. Notably, the expression of these miRNAs peaked at p194 in
LD 10–87 VERO cells.
The correlation of the six selected miRNAs for the tumori-
genic phenotype of VERO cells was veriﬁed by assessing another
independently-derived 10–87 VERO cell line that was developed
by HD passaging. The trend in the expression of signature miRNAs
was generally similar between the LD 10–87 VERO cell set and the
HD 10–87 VERO cell set. Moreover, the over-expression of these
miRNAs was  also evident in another VERO cell line, A4497 VERO
cells, that was also derived independently and has been shown to
be tumorigenic in newborn and adult nude mice [10]. Similar to our
previous report [28], the increased rate of migration of HD 10–87
VERO cells correlated with their capacity to form tumors in nude
mice. The transition of non-tumorigenic phenotype to tumorigenic
phenotype appeared to occur around p185 in 10–87 HD VERO cells
and around p194 in LD 10–87 VERO cells. Phenotypic differences
due to differential propagation of cell lines have been well docu-
mented with long-term sub-culturing resulting in divergent effects
on morphology, proliferation, development, and gene expression
[41–43]. Importantly, long-term propagation under high-density
(as compared with sub-conﬂuent) with extensive contact among
cells have been shown to increase their saturation density, increase
tumor incidence and decrease the latent period of tumor appear-
ance after injection of cells into mice [43–45]. The HD 10–87 VERO
cells formed tumors in NB and adult nude mice at p185 compared
with p194 for LD 10–87 VERO cells in NB mice. Since doubling time
for HD VERO cells was shorter (20 h) than LD VERO cells (26 h), it
is conceivable that the faster proliferation rate, driven by selec-
tive pressures, may  contribute to the enhanced tumor forming
capacity of HD VERO cells. However, the association of signature
miRNA over-expression appears to be related to the expression of
the VERO cell tumorigenic phenotype rather than to the passage
density or the reagents (tissue culture medium and serum) used
for cell culture. This correlation between the passage at which the
cells ﬁrst expressed a detectable tumorigenic phenotype and the
passage representing the peak expression levels of signature miR-
NAs illustrated that these miRNAs are potential biomarkers for the
expression of the VERO cell tumorigenic phenotype.
A comparison of the miRNA expression patterns between
tumorigenic VERO cells and its corresponding tumor tissue may
provide additional evidence supporting the speciﬁcity of the
miRNAs’ expression patterns to the expression of tumorigenic phe-
notype in VERO cells. In the present study, signature miRNAs were
not monitored in tumor tissue formed by injection of tumori-
genic VERO cells. However, a cell line established from a tumor
formed from LD VERO cells at p250 had the same pattern of miRNA
expression as the inoculated LD VERO cells [28]. Moreover, indi-
vidual miRNAs such as miR-376a have been reported as highly
expressed in different cancer tissues and cells when compared
with the corresponding normal tissues and cells [28,46–52]. Thus,
the concordance between the expression of signature miRNAs and
the miRNAs previously identiﬁed in other tumor tissues suggests
that these miRNAs are involved in the process of neoplastic devel-
opment in VERO cells. Although individual miRNAs alone can be
considered for use as a test for tumorigenic potential of VERO cells,
the diverse and complex molecular events involved in the initiation
and development of neoplasia argues against the use of individual
miRNAs as tumor biomarkers. Thus, we propose that these six miR-
NAs be used as a panel of biomarkers for tumorigenic VERO cells,
as the combination of these miRNAs may reﬂect various aspects of
tumorigenesis and form a more complete indicator of the VERO cell
tumorigenic phenotype.
Understanding how these six miRNAs contribute to the neoplas-
tic progression of VERO cells and their ability to form tumors would
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ontribute to their usefulness as biomarkers for the expression of
he VERO cell tumorigenic phenotype. Even though there are no
ata on the functions of these miRNAs in VERO cells, information
n their chromosomal locations and functions in other species is
vailable. All 6 of the miRNAs are located on human chromosome
4, and 4 of these 6 (miR-376a, miR-654-3P, miR-543, miR-229-
P) are found within the same 10 kb region of the chromosome.
hree of the 6 miRNAs (miR-299-3P, miR-134, miR-369-3P) are
p-regulated in human and murine embryonic stem cells [53–55],
uggesting a role in cellular dedifferentiation. Dedifferentiation has
een found to be the ﬁrst step in the repair of renal epithelium that
ccurs in vivo after acute kidney injury and in renal cells in pri-
ary culture [56,57]. As the expression of the 6 miRNAs increases
o their maximum levels after 170–180 passages of VERO cells
n concert with the expression of their tumorigenic phenotype,
e speculate that changes in miRNA expression up to and during
hese tumor-forming passage levels occurs as a component of the
ERO cell dedifferentiation processes involved in the expression of
he tumorigenic phenotype. Studies are underway to identify the
olecular pathways that might be altered by the over-expression
f these signature miRNAs in our VERO cell model.
In conclusion, with the goal of learning more about tumorigene-
is and reducing the use of animals for characterizing the neoplastic
henotype, we have demonstrated that proﬁling miRNA expression
redicts the tumorigenic potential of VERO cells as it evolves dur-
ng cell culture. Our observations point to a potential link between
iRNA proﬁles expressed in tumorigenic VERO cells and tumor
ormation in vivo, thereby indicating that miRNA proﬁling offers
romise as a surrogate for expression of VERO cell tumorigenic phe-
otype. Having a molecular assay for the evaluation of the ability of
mmortalized cell substrates to form tumors in vivo would provide a
uick and relatively inexpensive method for detecting the expres-
ion of the VERO cell tumorigenic phenotype. The identiﬁcation
f appropriate biomarkers could expedite the review of vaccines
anufactured in new immortalized mammalian cells. While the
elevance of the identiﬁed miRNA biomarkers was  shown here for
he 10–87 VERO cells that are being used as cell substrates for
icensed products, such biomarkers could be useful for the devel-
pment of new cell lines from the original VERO cell line or for the
evelopment of new lines of African green monkey cells for vaccine
anufacture; furthermore, they may  help reduce animal testing.
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